GlassScriptPhysician profile
Angela Urhammer
NPI 1881839108
$1,652.16
in general payments reported to CMS, 2019-2025
22 companies · $721 in 2025
The $721 reported for 2025 was more than what 80% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $157 · 2023: $125 · 2024: $649 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,495.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $216.66 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Saluda Medical Americas, INC. | $206.00 | 2024-2025 | Evoke |
| Alkermes, INC. | $179.89 | 2024-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $131.20 | 2023-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $120.79 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $107.97 | 2023-2025 | Rexulti, Abilify Maintena |
| Nevro Corp. | $94.50 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.72 | 2024-2025 | Trintellix |
| Tris Pharma INC | $76.53 | 2024-2025 | Dyanavel Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.76 | 2024-2025 | Caplyta |
| Pfizer INC. | $57.89 | 2021-2025 | |
| Medtronic, INC. | $54.23 | 2025 | Minimed 780g |
| Uswm, LLC | $52.28 | 2024 | Lucemyra |
| Lundbeck LLC | $37.56 | 2024 | Rexulti |
| Corium, LLC | $36.22 | 2023-2024 | Azstarys |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.89 | 2023-2024 | Xifaxan, Trulance |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.08 | 2025 | Rejoyn |
| Grt US Holding, INC. | $19.37 | 2021 | |
| Indivior INC. | $18.14 | 2024 | Perseris |
| Orexo US, INC. | $14.75 | 2024 | Zubsolv |
| Glaxosmithkline, LLC. | $14.21 | 2024 | Trelegy Ellipta |
| Collegium Pharmaceutical, INC. | $13.52 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Urhammer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.